Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study
Lists
Only you see this
Abstract
Pembrolizumab in combination with nab-paclitaxel and platinum demonstrated promising efficacy and a manageable safety profile in patients with R/M HNSCC. Future studies are warranted to confirm these findings.
BibTeX
@inproceedings{gui2024efficacy,
author = {Lin Gui and Xinrui Chen and Wen Zhang and Zucheng Xie and Yu Zhang and Weihua Li and Tongji Xie and Jiarui Yao and Haohua Zhu and Le Tang and Jianliang Yang and Peng Liu and Qin Yan and Changgong Zhang and Xiaohui He and Yuankai Shi},
title = {{Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study}},
booktitle = {Chinese},
year = {2024},
doi = {10.21147/j.issn.1000-9604.2024.06.09},
}Loading related content...